RxDoctor Payments Data

Charles Tucker, MD

Retina Specialist · Rock Hill, SCNPI 1033189501

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,964 of the $2,421 with a category attached, or 81.1%. 12 manufacturers reported payments, led by Genentech USA, Inc. at 35.2% of the total. Reporting peaked in 2022 at $936 and has fallen 88.2% since, to $110 in 2025. That places this record below the midpoint for retina specialist clinicians in SC, where the typical reported total is $2,421.

$2,421in general payments, 2019–2025

Across 85 payments — averaging $28.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$852
  • AbbVie$465
  • Notal Vision, Inc.$457
  • Coherus Oncology, Inc.$176
  • Biogen$115
  • Regeneron Healthcare Solutions, Inc.$92
  • plus $263 from 6 others

What the payments were for

  • Speaking & faculty fees$45719%
  • Food & beverage$1,96481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,421 in reported general payments places this provider in the 50th percentile of 20 retina specialist providers in South Carolina.

See all retina specialist providers in South Carolina

Medicare billing

Part B allowed, 2024
$2,640,341
Medicare patients
1,018
Services billed
59,897

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Bromfenac Sodium65$9,801
Prednisolone Acetate140$4,785
CombiganBrimonidine Tartrate/Timolol12$4,360
Loteprednol Etabonate22$4,341
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat102$1,719
Latanoprost101$1,258
Brimonidine Tartrate88$930
Fluorometholone12$840
Ketorolac Tromethamine26$819
Timolol Maleate52$352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCombigan$465$4,36012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 20 retina specialist providers in South Carolina.

Other retina specialist in Rock Hill

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →